2,869
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 14:02, 15 September 2023
, 15 September 2023→Studies
| Line 117: | Line 117: | ||
|- | |- | ||
|The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735188/</ref> | |The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735188/</ref> | ||
|[[RCT]], 60 days | |[[RCT]], 8.5 weeks (60 days) | ||
* placebo (n=20) | * placebo (n=20) | ||